Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer

Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04636788

Enrollment

102

Registered

2020-11-19

Start date

2020-11-01

Completion date

2022-11-01

Last updated

2020-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Adenocarcinoma

Keywords

exosome, snoRNA, endoscopic ultrasound, liquid biopsy

Brief summary

This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.

Detailed description

CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or other pancreatic lesions is not satisfying enough. Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably. By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.

Interventions

PROCEDUREVenous sampling

venous sampling of 12ml

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* age \>18 * pancreatic cancer patients * pancreatic lesions other than PAAD * chronic pancreatitis * cholangiocarcinoma

Exclusion criteria

* diagnosed with other pathological types of cancer * treated with chemo/radio/surgery previously

Design outcomes

Primary

Measure	Time frame	Description
senstivity	up to 8 weeks	sensitivity of exo-sRNA
specificity	up to 8 weeks	specificity of exo-sRNA to differentiate between PAAD and other benigh or malignant pancreatic occupying lesions

Secondary

Measure	Time frame	Description
survival time	up to 18 months	relationship between expression level of chosen exosomal RNA and patients' survival time in PAAD group

Countries

China

Contacts

Primary ContactBin Cheng, Professor

b.cheng@tjh.tjmu.edu.cn13986097542

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026